SCHEMBL30980583

SCHEMBL30980583

COC(=O)C(F)(F)c1cncc(Cl)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.35
NTRK1 P04629 1/20 0.34
PDE4B Q07343 5/20 0.34
PDE4A P27815 3/20 0.34
PDE4C Q08493 3/20 0.34
PDE4D Q08499 3/20 0.34
PDE11A Q9HCR9 1/20 0.34
CDK2 P24941 3/20 0.33
GRM5 P41594 1/20 0.33
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.31
ALPL P05186 1/20 0.31
ATF1 P18846 1/20 0.31
NFKB1 P19838 1/20 0.31
CNR2 P34972 1/20 0.31
GAA P10253 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
LATS1 O95835 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22924868 0.82 CYP2C19 (0.35) CSF1RNTRK1PDE4BPDE4APDE4C
SCHEMBL30416548 0.82 CYP2C19 (0.35) CSF1RNTRK1PDE4BPDE4APDE4C
SCHEMBL22924886 0.82 CSF1R (0.33) CSF1RNTRK1PDE4BPDE4APDE4C
SCHEMBL21384637 0.81 GRM5 (0.35) CSF1RNTRK1CDK2GRM5CYP2C19
SCHEMBL25259419 0.80 CDK2 (0.36) CSF1RNTRK1CDK2GRM5CYP11B1
SCHEMBL30528008 0.80 CDK2 (0.36) CSF1RNTRK1CDK2GRM5CYP11B1
SCHEMBL22924885 0.79 CYP2C19 (0.33) CSF1RCDK2GRM5CYP2C19CNR2
SCHEMBL30416534 0.79 CYP2C19 (0.33) CSF1RCDK2GRM5CYP2C19CNR2
SCHEMBL24768908 0.78 CDK2 (0.32) PDE4BPDE4APDE4CPDE4DCDK2
SCHEMBL29228053 0.76 ALOX5 (0.34) CDK2GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed